Epratuzumab May Work for SLE Subgroups

Larry Beresford is a medical journalist in Oakland, Calif.

References

1. Gottenberg JE, Dörner, T, Bootsma H, et al. Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjögren’s syndrome: Post hoc analyses from the EMBODY trials. Arthritis Rheumatol. 2018 May;70(5):763–773.
2. Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014 Jul 30;6:247–255.
3. Clowse ME, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III, randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017 Feb;69(2):362–375.
4. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183–190.
5. Clowse MEB, Wallace DJ, Furie R, et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: Results from two Phase 3 randomized, placebo-controlled trials (abstract 4L). Arthritis Rheumatol. 2015;67(suppl 10).
6. Statement on the results of epratuzumab study for the treatment of lupus. Lupus Foundation of America. 2015 Jul 28.
7. Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: Health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study. Rheumatology (Oxford). 2014 Mar;53(3):502–511.
8. Wallace D, Strand V, Furie R, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials: Development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint. Arthritis Rheumatol. 2011;63(suppl 10):S894.
9. Geh D, Gordon C. Epratuzumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol. 2018 Apr;14(4):245–258.
10. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: An open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129.